CONTEXT: Deep brain stimulation (DBS) may be an effective intervention for treatment-resistant depression (TRD), but available data are limited. OBJECTIVE: To assess the efficacy and safety of subcallosal cingulate DBS in patients with TRD with either major depressive disorder (MDD) or bipolar II disorder (BP). DESIGN: Open-label trial with a sham lead-in phase. SETTING: Academic medical center. Patients Men and women aged 18 to 70 years with a moderate-to-severe major depressive episode after at least 4 adequate antidepressant treatments. Ten patients with MDD and 7 with BP were enrolled from a total of 323 patients screened. Intervention Deep brain stimulation electrodes were implanted bilaterally in the subcallosal cingulate white matter. Patients received single-blind sham stimulation for 4 weeks followed by active stimulation for 24 weeks. Patients then entered a single-blind discontinuation phase; this phase was stopped after the first 3 patients because of ethical concerns. Patients were evaluated for up to 2 years after the onset of active stimulation. MAIN OUTCOME MEASURES: Change in depression severity and functioning over time, and response and remission rates after 24 weeks were the primary efficacy end points; secondary efficacy end points were 1 year and 2 years of active stimulation. RESULTS: A significant decrease in depression and increase in function were associated with chronic stimulation. Remission and response were seen in 3 patients (18%) and 7 (41%) after 24 weeks (n = 17), 5 (36%) and 5 (36%) after 1 year (n = 14), and 7 (58%) and 11 (92%) after 2 years (n = 12) of active stimulation. No patient achieving remission experienced a spontaneous relapse. Efficacy was similar for patients with MDD and those with BP. Chronic DBS was safe and well tolerated, and no hypomanic or manic episodes occurred. A modest sham stimulation effect was found, likely due to a decrease in depression after the surgical intervention but prior to entering the sham phase. CONCLUSIONS: The findings of this study support the long-term safety and antidepressant efficacy of subcallosal cingulate DBS for TRD and suggest equivalent safety and efficacy for TRD in patients with BP. Trial Registration clinicaltrials.gov Identifier: NCT00367003.
RCT Entities:
CONTEXT: Deep brain stimulation (DBS) may be an effective intervention for treatment-resistant depression (TRD), but available data are limited. OBJECTIVE: To assess the efficacy and safety of subcallosal cingulate DBS in patients with TRD with either major depressive disorder (MDD) or bipolar II disorder (BP). DESIGN: Open-label trial with a sham lead-in phase. SETTING: Academic medical center. PatientsMen and women aged 18 to 70 years with a moderate-to-severe major depressive episode after at least 4 adequate antidepressant treatments. Ten patients with MDD and 7 with BP were enrolled from a total of 323 patients screened. Intervention Deep brain stimulation electrodes were implanted bilaterally in the subcallosal cingulate white matter. Patients received single-blind sham stimulation for 4 weeks followed by active stimulation for 24 weeks. Patients then entered a single-blind discontinuation phase; this phase was stopped after the first 3 patients because of ethical concerns. Patients were evaluated for up to 2 years after the onset of active stimulation. MAIN OUTCOME MEASURES: Change in depression severity and functioning over time, and response and remission rates after 24 weeks were the primary efficacy end points; secondary efficacy end points were 1 year and 2 years of active stimulation. RESULTS: A significant decrease in depression and increase in function were associated with chronic stimulation. Remission and response were seen in 3 patients (18%) and 7 (41%) after 24 weeks (n = 17), 5 (36%) and 5 (36%) after 1 year (n = 14), and 7 (58%) and 11 (92%) after 2 years (n = 12) of active stimulation. No patient achieving remission experienced a spontaneous relapse. Efficacy was similar for patients with MDD and those with BP. Chronic DBS was safe and well tolerated, and no hypomanic or manic episodes occurred. A modest sham stimulation effect was found, likely due to a decrease in depression after the surgical intervention but prior to entering the sham phase. CONCLUSIONS: The findings of this study support the long-term safety and antidepressant efficacy of subcallosal cingulate DBS for TRD and suggest equivalent safety and efficacy for TRD in patients with BP. Trial Registration clinicaltrials.gov Identifier: NCT00367003.
Authors: Helen S Mayberg; Andres M Lozano; Valerie Voon; Heather E McNeely; David Seminowicz; Clement Hamani; Jason M Schwalb; Sidney H Kennedy Journal: Neuron Date: 2005-03-03 Impact factor: 17.173
Authors: Sidney H Kennedy; Peter Giacobbe; Sakina J Rizvi; Franca M Placenza; Yasunori Nishikawa; Helen S Mayberg; Andres M Lozano Journal: Am J Psychiatry Date: 2011-02-01 Impact factor: 18.112
Authors: T W Robbins; M James; A M Owen; B J Sahakian; A D Lawrence; L McInnes; P M Rabbitt Journal: J Int Neuropsychol Soc Date: 1998-09 Impact factor: 2.892
Authors: Mark S George; A John Rush; Lauren B Marangell; Harold A Sackeim; Stephen K Brannan; Sonia M Davis; Robert Howland; Mitchel A Kling; Francisco Moreno; Barry Rittberg; David Dunner; Thomas Schwartz; Linda Carpenter; Michael Burke; Philip Ninan; Paul Goodnick Journal: Biol Psychiatry Date: 2005-09-01 Impact factor: 13.382
Authors: Takashi Morishita; Kelly D Foote; Samuel S Wu; Charles E Jacobson; Ramon L Rodriguez; Ihtsham U Haq; Mustafa S Siddiqui; Irene A Malaty; Christopher J Hass; Michael S Okun Journal: J Neurosurg Date: 2010-03 Impact factor: 5.115
Authors: Donald A Malone; Darin D Dougherty; Ali R Rezai; Linda L Carpenter; Gerhard M Friehs; Emad N Eskandar; Scott L Rauch; Steven A Rasmussen; Andre G Machado; Cynthia S Kubu; Audrey R Tyrka; Lawrence H Price; Paul H Stypulkowski; Jonathon E Giftakis; Mark T Rise; Paul F Malloy; Stephen P Salloway; Benjamin D Greenberg Journal: Biol Psychiatry Date: 2008-10-08 Impact factor: 13.382
Authors: Clement Hamani; Helen Mayberg; Brian Snyder; Peter Giacobbe; Sidney Kennedy; Andres M Lozano Journal: J Neurosurg Date: 2009-12 Impact factor: 5.115
Authors: David A Gutman; Paul E Holtzheimer; Timothy E J Behrens; Heidi Johansen-Berg; Helen S Mayberg Journal: Biol Psychiatry Date: 2008-11-14 Impact factor: 13.382
Authors: James M Broadway; Paul E Holtzheimer; Matthew R Hilimire; Nathan A Parks; Jordan E Devylder; Helen S Mayberg; Paul M Corballis Journal: Neuropsychopharmacology Date: 2012-03-14 Impact factor: 7.853
Authors: Ahmad Alhourani; Michael M McDowell; Michael J Randazzo; Thomas A Wozny; Efstathios D Kondylis; Witold J Lipski; Sarah Beck; Jordan F Karp; Avniel S Ghuman; R Mark Richardson Journal: J Neurophysiol Date: 2015-08-12 Impact factor: 2.714
Authors: Clement Hamani; Danilo C Machado; Débora C Hipólide; Francisco P Dubiela; Deborah Suchecki; Carlos E Macedo; Fabio Tescarollo; Uilton Martins; Luciene Covolan; José N Nobrega Journal: Biol Psychiatry Date: 2011-10-14 Impact factor: 13.382
Authors: Matthew R Hilimire; Helen S Mayberg; Paul E Holtzheimer; James M Broadway; Nathan A Parks; Jordan E DeVylder; Paul M Corballis Journal: Brain Stimul Date: 2014-11-24 Impact factor: 8.955